Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | OXTR | P30559 | 5/20 | 0.37 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.37 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2117226 | 0.87 | CYP2C9 (0.39) | ACSS2CYP2C9KDM4EPOLBLMNA | |
| SCHEMBL2120046 | 0.86 | CYP2C9 (0.37) | ACSS2CYP2C9KDM4EPOLBLMNA | |
| SCHEMBL2118249 | 0.79 | PSEN1 (0.45) | CYP2C9KDM4ELMNACA1CA2 | |
| SCHEMBL2117866 | 0.79 | TAAR1 (0.47) | CYP2C9KDM4EPOLBLMNATRIM24 | |
| SCHEMBL2117311 | 0.79 | HSD17B1 (0.43) | CYP2C9KDM4ELMNATRIM24 | |
| SCHEMBL2118182 | 0.78 | TRIM24 (0.54) | ACSS2POLBLMNATRIM24 | |
| SCHEMBL2117789 | 0.75 | KCNH2 (0.38) | KCNH2CYP2C9LMNAOXTRAVPR2 | |
| SCHEMBL13575348 | 0.72 | MEN1 (0.47) | ACSS2KDM4EPOLBCA1CA2 | |
| SCHEMBL2119290 | 0.67 | TRIM24 (0.55) | CYP2C9KDM4EPOLBLMNATRIM24 | |
| SCHEMBL2116901 | 0.66 | TRIM24 (0.49) | CYP2C9POLBTRIM24 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095012-A1 | TOLUIDINE SULFONAMIDES AND THEIR USE | ELARA PHARMACEUTICALS GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
| EP-2382190-A1 | TOLUIDINE SULFONAMIDES AND THEIR USE AS-INHIBITORS | European Molecular Biology Laboratory (EMBL) (DE) | 2011-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095012-A1 | TOLUIDINE SULFONAMIDES AND THEIR USE | HIF1A, HIF1AN, EGLN3 | ACSS2 806/4885KCNH2 3023/4885CYP2C9 2049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.